Intended for healthcare professionals

Letters Screening for hepatitis C

Authors’ reply to Selvapatt and colleagues, Matthews and colleagues, Badrinath, and Ward and Lee

BMJ 2015; 350 doi: (Published 24 February 2015) Cite this as: BMJ 2015;350:h674
  1. Ronald L Koretz, emeritus professor of clinical medicine1,
  2. Kenneth W Lin, associate professor of family medicine2,
  3. John P A Ioannidis, professor of medicine3,
  4. Jeanne Lenzer, medical investigative journalist4
  1. 1David Geffen-UCLA School of Medicine, CA, USA
  2. 2Georgetown University School of Medicine, Washington, DC, USA
  3. 3Stanford University, CA, USA
  4. 4New York, USA
  1. jeanne.lenzer{at}

Selvapatt and colleagues made several points: large numbers of people are infected; birth cohort screening is cost effective; previously treated patients without severe fibrosis are unlikely to progress; sustained virological response improves quality of life; treatment reduces mortality; and newer agents have fewer side effects (last two also alluded to by Matthews and colleagues).1 2 3 The number of patients is not the issue, which is whether …

View Full Text

Log in

Log in through your institution


* For online subscription